Rajat Bose of rajatkbose.com told CNBC-TV18, "Sun Pharmaceutical Advanced Research Company (SPARC) from a valuation point of view, from a correction and then a rebound point of view looks better. So, put a stop loss below Rs 342.80 and your targets could be Rs 350 and Rs 354 on the upside. So, these are the two targets I have. SPARC is recovering from a correction and has a much better potential once it stays above Rs 354."
At 12:19 hrs Sun Pharma Advanced Research Company was quoting at Rs 346.00, up Rs 2.45, or 0.71 percent. It has touched an intraday high of Rs 348.70 and an intraday low of Rs 344.05.
